Omecamtiv mecarbil

Phase 3Small molecule

Novartis

Omecamtiv mecarbil is one of 23 small molecule programs targeting Heart Failure. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureRecruiting

Heart FailurePhase 3

Recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Omecamtiv mecarbil

Novartis

Phase 3

7 2

Brethine

Sanofi

Preclinical

1 3

Amidate

Pfizer

Preclinical

1 4

LCZ696

Novartis

Preclinical

15 5

Zemplar

AbbVie

Preclinical

—6

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 7

Xifaxan

SSalix

Preclinical

2 8

Zoloft

VViatris Specialty LLC

Preclinical

2 9

Coumadin

AAbbott

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Heart Failure

NCT06736574

Clinical

Trials by Indication[1]

Heart Failure7 trials

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

Completed·CCytokinetics·Phase 3·NCT02929329·8,256 enrolled

Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

Completed·CCytokinetics·Phase 2·NCT02695420·81 enrolled

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

Completed·CCytokinetics·Phase 2·NCT01786512·544 enrolled

Show 4 more trials

Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients

Withdrawn·CCytokinetics·Phase 2·NCT01077167

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

Completed·CCytokinetics·Phase 3·NCT03759392·276 enrolled

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

Completed·CCytokinetics·Phase 2·NCT01300013·614 enrolled

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)

Recruiting·CCytokinetics·Phase 3·NCT06736574·1,800 enrolled

Adult2 trials

Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults

Completed·CCytokinetics·Phase 1·NCT04175808·70 enrolled

Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults

Completed·CCytokinetics·Phase 1·NCT02601001·50 enrolled

Pregabalin1 trial

Reducing Postoperative Side Effect of Pregabalin

Completed·TThe First Hospital of Jilin University·Phase 4·NCT04599894·58 enrolled

Trial1 trial

Omecamtiv Mecarbil Post-trial Access Study

Withdrawn·CCytokinetics·Phase 3·NCT04464525

CAR1 trial

A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers

Completed·CCytokinetics·Phase 1·NCT01380223·35 enrolled

1 more indication

Unspecified1 trial

A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device

Completed· Novartis logo

Novartis·Phase 2·NCT01484197·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Omecamtiv mecarbil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omecamtiv mecarbil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omecamtiv mecarbil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Omecamtiv mecarbil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Heart Failure7 trials

Adult2 trials

Pregabalin1 trial

Trial1 trial

CAR1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News